Lucid Diagnostics (NASDAQ:LUCD) Rating Increased to Hold at Wall Street Zen

Lucid Diagnostics (NASDAQ:LUCD) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Other equities analysts have also recently issued reports about the stock. BTIG Research raised their target price on shares of Lucid Diagnostics from $2.00 to $2.50 and gave the company a “buy” rating in a research note on Friday, September 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research note on Wednesday, August 13th. Finally, Ascendiant Capital Markets increased their price objective on shares of Lucid Diagnostics from $7.50 to $7.75 and gave the company a “buy” rating in a research report on Friday, June 6th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $3.65.

Lucid Diagnostics Stock Performance

LUCD opened at $1.03 on Friday. The stock has a market capitalization of $137.48 million, a price-to-earnings ratio of -0.87 and a beta of 1.24. The company has a fifty day moving average of $1.09 and a 200 day moving average of $1.23. Lucid Diagnostics has a fifty-two week low of $0.75 and a fifty-two week high of $1.80.

Insider Activity

In other news, Director Dennis Matheis bought 100,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was purchased at an average price of $1.02 per share, for a total transaction of $102,000.00. Following the acquisition, the director owned 665,443 shares of the company’s stock, valued at $678,751.86. The trade was a 17.69% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 6.80% of the company’s stock.

Institutional Investors Weigh In On Lucid Diagnostics

Several institutional investors have recently made changes to their positions in LUCD. Citadel Advisors LLC bought a new stake in shares of Lucid Diagnostics in the 4th quarter worth about $98,000. XML Financial LLC bought a new stake in shares of Lucid Diagnostics in the 1st quarter worth about $266,000. Berkshire Asset Management LLC PA bought a new stake in shares of Lucid Diagnostics in the 1st quarter worth about $30,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Lucid Diagnostics in the 1st quarter worth about $37,000. Finally, Ghisallo Capital Management LLC bought a new stake in shares of Lucid Diagnostics in the 1st quarter worth about $629,000. Institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.